Bausch Health Companies Inc. (BHC)

NYSE: BHC · IEX Real-Time Price · USD
+0.19 (2.07%)
At close: Feb 29, 2024, 4:00 PM
-0.04 (-0.43%)
After-hours: Feb 29, 2024, 4:31 PM EST

Company Description

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.

It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.

The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally.

The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States.

The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products.

The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.

Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc.
Bausch Health Companies logo
Country Canada
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 20,270
CEO Thomas J. Appio

Contact Details

2150 St. Elzear Blvd. West, Laval
Quebec, A8 H7L 4A8
Quebec, Canada
Phone 514-744-6792

Stock Details

Ticker Symbol BHC
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000885590
CUSIP Number 071734107
ISIN Number CA0717341071
SIC Code 2834

Key Executives

Name Position
Thomas J. Appio Chief Executive Officer and Director
John S. Barresi Senior Vice President, Controller, Chief Accounting Officer and Interim Chief Financial Officer
Mirza Dautbegovic Senior Vice President and Chief Operating Officer
Josh Coyle Senior Vice President of Sales and Salix
Kathleen Fitzpatrick Senior Vice President and Chief Human Resources Officer
Dr. Tage Ramakrishna M.D. Chief Medical Officer and President of Research & Development
Jeff Hartness Executive Vice President of Market Access, Commercial Operations, Neurology, Generics and Government Affairs
Dr. Graham Jackson Senior Vice President and Chief Quality Officer
Cees Heiman Senior Vice President of Europe and Canada
Donald Pearl Senior Vice President of Ortho Dermatologics

Latest SEC Filings

Date Type Title
Feb 22, 2024 10-K Annual Report
Feb 22, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 1, 2024 8-K Current Report
Dec 5, 2023 144 Filing
Nov 13, 2023 8-K/A [Amend] Current report
Nov 6, 2023 144 Filing
Nov 2, 2023 10-Q Quarterly Report
Nov 2, 2023 8-K Current Report